We further tested the efficacy of indisulam and anti-GD2 mAb in two additional neuroblastoma syngeneic models: Dbh-iCre:LSL-MYCN model (C57BL6 background)89 and a temozolomide-resistant Th-MYCN model (129 × 1/SvJ background). Here, MYCN is linked to neuroblastoma.